Search Results - "Gan, Hui K"

Antibody-Drug Conjugates for Cancer Therapy by Hafeez, Umbreen, Parakh, Sagun, Gan, Hui K, Scott, Andrew M

“…Antibody-drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells…”
Get full text

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered by Gan, Hui K., Cvrljevic, Anna N., Johns, Terrance G.

“…The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with…”
Get full text

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors by Arnaud‐Coffin, Patrick, Maillet, Denis, Gan, Hui K., Stelmes, Jean‐Jacques, You, Benoit, Dalle, Stephane, Péron, Julien

“…The advent of immune checkpoint‐inhibitors (CPI) has transformed treatment for several cancer types. This review was performed to assess the rate of adverse…”
Get full text

Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells by Gan, Hui K., van den Bent, Martin, Lassman, Andrew B., Reardon, David A., Scott, Andrew M.

“…Key Points Cell-surface antigens expressed on glioblastoma cells that have proven resistant to signalling inhibition approaches — whether by tyrosine-kinase…”
Get full text

The EGFRvIII variant in glioblastoma multiforme by Gan, Hui K, Kaye, Andrew H, Luwor, Rodney B

“…Abstract Glioblastoma multiforme (GBM) is the most common brain tumour and has the worst prognosis. Epidermal growth factor receptor (EGFR) gene amplification,…”
Get full text

Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy by GAN, Hui K, BURGESS, Antony W, CLAYTON, Andrew H. A, SCOTT, Andrew M

“…Epidermal growth factor receptor (EGFR) and its most common extracellular mutant, EGFRvIII, are important therapeutic targets in multiple cancer types. A…”
Get full text

Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review by PERON, Julien, MAILLET, Denis, GAN, Hui K, CHEN, Eric X, YOU, Benoit

“…The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding…”
Get full text

Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review by YOU, Benoit, GAN, Hui K, POND, Gregory, CHEN, Eric X

“…To improve the quality of reporting of randomized clinical trials (RCTs), international registries for RCTs and guidelines for primary end point (PEP) analysis…”
Get full text

Antibody Targeting of Eph Receptors in Cancer by Janes, Peter W, Vail, Mary E, Gan, Hui K, Scott, Andrew M

“…The Eph subfamily of receptor tyrosine kinases mediate cell-cell communication controlling cell and tissue patterning during development. While generally less…”
Get full text

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors by Gan, Hui K., Millward, Michael, Jalving, Mathilde, Garrido‐Laguna, Ignacio, Lickliter, Jason D., Schellens, Jan H.M., Lolkema, Martijn P., Van Herpen, Carla L.M., Hug, Bruce, Tang, Lihua, O'Connor‐Semmes, Robin, Gagnon, Robert, Ellis, Catherine, Ganji, Gopinath, Matheny, Christopher, Drilon, Alexander

“…Background GSK2849330, an anti‐HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signaling in cancer cells, is engineered for enhanced…”
Get full text

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography by Dickmann, Catherine G Fitzgerald, McDonald, Alexander F, Huynh, Nhi, Rigopoulos, Angela, Liu, Zhanqi, Guo, Nancy, Osellame, Laura D, Gorman, Michael A, Parker, Michael W, Gan, Hui K, Scott, Andrew M, Ackermann, Uwe, Burvenich, Ingrid J G, White, Jonathan M

“…Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been…”
Get more information

Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry) by Gately, Lucy, Drummond, Katharine, Rosenthal, Mark, Harrup, Rosemary, Dowling, Anthony, Gogos, Andrew, Lwin, Zarnie, Collins, Ian, Campbell, David, Ahern, Elizabeth, Phillips, Claire, Gan, Hui K, Bennett, Iwan, Sieber, Oliver M, Gibbs, Peter

“…Real-world data (RWD) is increasingly being embraced as an invaluable source of information to address clinical and policy-relevant questions that are unlikely…”
Get full text

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate by Phillips, Andrew C, Boghaert, Erwin R, Vaidya, Kedar S, Falls, Hugh D, Mitten, Michael J, DeVries, Peter J, Benatuil, Lorenzo, Hsieh, Chung-Ming, Meulbroek, Jonathan A, Panchal, Sanjay C, Buchanan, Fritz G, Durbin, Kenneth R, Voorbach, Martin J, Reuter, David R, Mudd, Sarah R, Loberg, Lise I, Ralston, Sherry L, Cao, Diana, Gan, Hui K, Scott, Andrew M, Reilly, Edward B

“…Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl…”
Get full text

Antibody-Drug Conjugates for Cancer Therapy by Parslow, Adam C, Parakh, Sagun, Lee, Fook-Thean, Gan, Hui K, Scott, Andrew M

“…Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The…”
Get full text

Antibody-drug conjugates: beyond current approvals and potential future strategies by Menon, Siddharth, Parakh, Sagun, Scott, Andrew M., Gan, Hui K.

“…The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs…”
Get full text

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents by Le Tourneau, Christophe, Gan, Hui K, Razak, Albiruni R A, Paoletti, Xavier

“…Statistical simulations have consistently demonstrated that new dose-escalation designs such as accelerated titration design (ATD) and continual reassessment…”
Get full text

[ 18 F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial by Koh, Eng-Siew, Gan, Hui K, Senko, Clare, Francis, Roslyn J, Ebert, Martin, Lee, Sze Ting, Lau, Eddie, Khasraw, Mustafa, Nowak, Anna K, Bailey, Dale L, Moffat, Bradford A, Fitt, Greg, Hicks, Rodney J, Coffey, Robert, Verhaak, Roel, Walsh, Kyle M, Barnes, Elizabeth H, De Abreu Lourenco, Richard, Rosenthal, Mark, Adda, Lucas, Foroudi, Farshad, Lasocki, Arian, Moore, Alisha, Thomas, Paul A, Roach, Paul, Back, Michael, Leonard, Robyn, Scott, Andrew M

“…Glioblastoma is the most common aggressive primary central nervous system cancer in adults characterised by uniformly poor survival. Despite maximal safe…”
Get full text

Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma by Gougis, Paul, Moreau Bachelard, Camille, Kamal, Maud, Gan, Hui K, Borcoman, Edith, Torossian, Nouritza, Bièche, Ivan, Le Tourneau, Christophe

“…A better understanding of cancer biology has led to the development of molecular targeted therapy, which has dramatically improved the outcome of some cancer…”
Get full text

Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer by Gan, Hui K., M.B.B.S, Bernstein, Lori J., Ph.D, Brown, Jennifer, M.A, Ringash, Jolie, M.D, Vakilha, Mehrdad, M.D, Wang, Lisa, M.Sc, Goldstein, David, M.D, Kim, John, M.D, Hope, Andrew, M.D, O'Sullivan, Brian, M.D, Waldron, John, M.D, Abdul Razak, Albiruni R., M.D, Chen, Eric X., M.D, Siu, Lillian L., M.D

“…Purpose To perform a comprehensive cognitive function (CF) assessment in patients who were relapse free after curative intent radiotherapy (RT) or…”
Get full text

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma by Kong, Benjamin Y, Sim, Hao-Wen, Barnes, Elizabeth H, Nowak, Anna K, Hovey, Elizabeth J, Jeffree, Rosalind, Harrup, Rosemary, Parkinson, Jonathon, Gan, Hui K, Pinkham, Mark B, Yip, Sonia, Hall, Merryn, Tu, Emily, Carter, Candace, Koh, Eng-Siew, Lwin, Zarnie, Dowling, Anthony, Simes, John S, Gedye, Craig

“…IntroductionGlioblastoma (GBM) is the most common malignant primary central nervous system cancer in adults. The objective of the Multi-Arm GlioblastoMa…”
Get full text